Adjuvant mitotane did not yield a significantly reduced risk of recurrence among patients with adrenocortical carcinoma.
Janelle Hart
Advertisement
Articles by Janelle Hart
Advertisement
Latest Updated Articles
Adjuvant Mitotane Misses RFS End Point in Adrenocortical CarcinomaFebruary 27th 2022
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Survey Highlights Need for Nurse Autonomy in Multiple Myeloma Care
2
FDA Approves Tregzi for Chronic GVHD-Free Survival in Blood Cancer
3
Sun Safety in Oncology: Strategies for Education and Risk Assessment
4
Accelerated Biological Aging Linked to Rising Early-Onset Cancer Risk
5